Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul G Richardson

Showing results (1-10 of 542) with videos related to

Pageof 55
Sort By:
The Lancet. Oncology|April 7, 2016
Dual inhibition of oncogenic targets for B-cell malignanciesPaul G Richardson
Lancet (London, England)|December 15, 2010
A new standard of care in newly diagnosed multiple myelomaPaul G Richardson
Oncology (Williston Park, N.Y.)|August 17, 2016
Point/Counterpoint: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma. One Size does not fit allPaul G Richardson
Journal of Oncology Practice|April 14, 2016
The Future of Myeloma Therapy: One Size Does Not Fit AllPaul G Richardson
Clinical Advances in Hematology & Oncology : H&O|May 2, 2008
The myeloma landscape in 2008Paul G Richardson
Clinical Advances in Hematology & Oncology : H&O|June 14, 2014
Update on proteasome inhibitors in multiple myelomaPaul G Richardson
Blood|December 4, 2010
Improving the therapeutic index in myelomaPaul G Richardson
Expert Opinion on Pharmacotherapy|May 28, 2004
A review of the proteasome inhibitor bortezomib in multiple myelomaPaul G Richardson
The Lancet. Oncology|November 6, 2010
Towards a better understanding of treatment-related peripheral neuropathy in multiple myelomaPaul G Richardson
Clinical Advances in Hematology & Oncology : H&O|July 29, 2020
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple MyelomaPaul G Richardson
Pageof 55

Showing results (1-10 of 542) with videos related to

Sort By:
Pageof 55
The Lancet. Oncology|April 7, 2016
Dual inhibition of oncogenic targets for B-cell malignanciesPaul G Richardson
Lancet (London, England)|December 15, 2010
A new standard of care in newly diagnosed multiple myelomaPaul G Richardson
Oncology (Williston Park, N.Y.)|August 17, 2016
Point/Counterpoint: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma. One Size does not fit allPaul G Richardson
Journal of Oncology Practice|April 14, 2016
The Future of Myeloma Therapy: One Size Does Not Fit AllPaul G Richardson
Clinical Advances in Hematology & Oncology : H&O|May 2, 2008
The myeloma landscape in 2008Paul G Richardson
Clinical Advances in Hematology & Oncology : H&O|June 14, 2014
Update on proteasome inhibitors in multiple myelomaPaul G Richardson
Blood|December 4, 2010
Improving the therapeutic index in myelomaPaul G Richardson
Expert Opinion on Pharmacotherapy|May 28, 2004
A review of the proteasome inhibitor bortezomib in multiple myelomaPaul G Richardson
The Lancet. Oncology|November 6, 2010
Towards a better understanding of treatment-related peripheral neuropathy in multiple myelomaPaul G Richardson
Clinical Advances in Hematology & Oncology : H&O|July 29, 2020
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple MyelomaPaul G Richardson
Pageof 55